News
Zacks Investment Research on MSN4h
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
GoPro, Krispy Kreme, and Kohl’s surge as meme stock mania returns. Retail traders drive volatility in a high-liquidity, ...
Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...
Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...
Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback